# Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

> **NCT02322866** · PHASE3 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 1034 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Sarecycline
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02322866
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-03
- **Primary completion:** 2017-01-12
- **Final completion:** 2017-01-12
- **Target enrollment:** 1034 (ACTUAL)
- **Last updated:** 2019-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322866, "Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02322866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*